Double-digit growth and improving profitability to drive earnings in FY23
While there are multiple positives across SRF's key segments, investors should await for a better opportunity to enter the stock
Cash deployment and valuation upside for new business/investee firms are other triggers
Both residential and leasing trends point to strong showing in FY23
A YoY fall in volumes in the March quarter would be a first in seven quarters
Though the stock has gained 35% over the past month, given that target prices of brokerages range between Rs 410-Rs 450 a share, there is still an upside of over 37% likely from the current levels
While pricing action is expected, margins may remain under pressure for Voltas.
Rerating on the cards; the domestic business is expected to outperform
The stock remains one of the top picks among brokerages in the mid-cap IT space
While earnings estimates are cut, analysts hint at volume and margin recovery
Turnaround hopes and attractive valuations, however, keep the Street positive on the stock
Distribution yields could go up but risk of covid infection, interest rates remain
Progress on US sales will be key for further Torrent Pharma's stock gains
Lower copra costs and price cuts to aid volumes and margins
Inability to pass on the entire cost will squeeze margins
At the current price, the stock is trading at 30x its FY23 earnings estimates
Higher exports may offset some of the volume, cost pressure
Buyback could support the price in the near term
US price erosion, India growth trends would be keenly tracked
Rental renegotiations another dampener for the stock